{"id":"NCT03103087","sponsor":"Myovant Sciences GmbH","briefTitle":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","officialTitle":"LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-14","primaryCompletion":"2019-07-10","completion":"2020-09-16","firstPosted":"2017-04-06","resultsPosted":"2022-04-20","lastUpdate":"2022-04-20"},"enrollment":382,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heavy Menstrual Bleeding","Uterine Fibroid"],"interventions":[{"type":"DRUG","name":"Relugolix","otherNames":["TAK-385","MVT-601"]},{"type":"DRUG","name":"Estradiol/norethindrone acetate","otherNames":["E2/NETA","low-dose hormonal add-back"]},{"type":"DRUG","name":"Relugolix placebo","otherNames":[]},{"type":"DRUG","name":"Estradiol/norethindrone acetate placebo","otherNames":["E2/NETA placebo"]}],"arms":[{"label":"Relugolix plus E2/NETA (Group A)","type":"EXPERIMENTAL"},{"label":"Relugolix plus Delayed E2/NETA (Group B)","type":"EXPERIMENTAL"},{"label":"Placebo (Group C)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.","primaryOutcome":{"measure":"Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A â‰¥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA","timeFrame":"From Baseline up to the last 35 days of treatment (up to Week 24)","effectByArm":[{"arm":"Relugolix Plus E2/NETA (Group A)","deltaMin":71.2,"sd":null},{"arm":"Placebo (Group C)","deltaMin":14.73,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":127,"countries":["United States","Belgium","Brazil","Chile","Czechia","Hungary","Poland","South Africa"]},"refs":{"pmids":["39466126","37863160","37477173","37183454","36357960","35675604","35415708","33596357"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":126},"commonTop":["Hot flush","Headache","Nausea","Hypertension","Upper respiratory tract infection"]}}